Recordati is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals for primary care as well as orphan drugs for the treatment of rare diseases. Headquartered in Milan, the group has a staff of around 4,000 and has operations in the main European countries, in Central and Eastern Europe, in Turkey, in North Africa and in the U.S.A.. Recordati has been listed on the Italian Stock Exchange since 1984.
Recordati offers a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized segment dedicated to treatments for rare diseases. An efficient field force of medical representatives promotes these products in all countries where subsidiaries have been established. The company's leading products are drugs for the treatment of hypertension and other cardiovascular disorders as well as treatments for disorders of the lower urinary tract such as benign prostatic hyperplasia. Drugs for rare diseases are mainly treatments for metabolic deficiencies of a genetic nature. Recordati sells its proprietary pharmaceuticals directly to the market in the countries where it is present and through licensees elsewhere. Pharmaceutical production is based mainly in Italy (Milan), France (Montluçon) Turkey (Esenyurt), in Spain (Zaragoza) and in Tunisia (Ariana). Plants for the production of proprietary active ingredients are situated in Italy (Campoverde, Latina) and in Cork (Ireland).
Research and development activities are concentrated on urology and in particular benign prostatic hyperplasia, on cancer-related pain and on the area of rare diseases where innovative programs in onco-hematology are ongoing.
Recordati also has a minor pharmaceutical chemicals business. Recordati produces active ingredients for both its own proprietary pharmaceuticals and for the generic drugs industry. Over 90% of third party production is for the export markets.
Key consolidated data
- Consolidated revenue for 2013 is € 941.6 million.
- Operating income for 2013 is € 195.4 million.
- Net income for 2013 is € 133.7 million.
- Expand through organic development and through acquisitions.
- Pursue geographical expansion by entering new markets characterized by high growth potential.
Develop the business dedicated to treatment of rare diseases on a worldwide basis.